Bill Haney, Dragonfly CEO (Dave Pedley/Getty Images for SXSW)
February 7, 2023 06:35 AM ESTUpdated 07:39 AM
Deals
Bioregnum

Drag­on­fly chief: Bris­tol My­ers shouldn’t blame IL-12’s clin­i­cal per­for­mance for de­ci­sion to scrap the deal — eco­nom­ics played a key role

Bris­tol My­ers Squibb says the IL-12 drug they were de­vel­op­ing out of Drag­on­fly Ther­a­peu­tics was scrubbed from the pipeline for a sim­ple rea­son: It …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times